TICKERNERD
Menu
MLABMLABTechnology · Scientific & Technical Instruments

MLAB Stock Forecast: Mesa Laboratories, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$121
−0.03% on the day

The 3 Wall Street analysts covering Mesa Laboratories, Inc. hold a median 12-month price target of $118 — -2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 10 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$676.6M
Ticker Nerd rank
91 / 100
Median analyst target
$118
Analysts covering
3
Revenue$60.1M+1.0% y/y
Operating income$7.0M
Net income$2.8M
Free cash flow$14.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.0%
1M
+8.8%
YTD
+54.8%
1Y
+93.0%
From 52W high
−7.5%
From 52W low
+97.5%
$61
$131
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MLAB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mesa Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Value
88
Quality
86
Issuance
83
Volatility
78
Momentum
70
Growth
58
Size
50
Revisions
31

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (31): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MLAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26MLABHigh $125Median $118Low $110

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $110Median $118High $125

The green dot is the last close — the median target sits −2.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Wells FargoMaintainsEqual-Weight$94 → $110
4 Feb 2026Wells FargoMaintainsEqual-Weight$83 → $94
4 Feb 2026Wells FargoMaintainsEqual-Weight—
15 Dec 2025Wells FargoMaintainsEqual-Weight—
8 Aug 2025Wells FargoUpgradeEqual-Weight—
30 May 2025Wells FargoMaintainsUnderweight—
1 Oct 2024Evercore ISI GroupMaintainsOutperform—
27 Aug 2024Wells FargoInitiatesUnderweight—
6 Aug 2024Evercore ISI GroupMaintainsOutperform—
2 July 2024Evercore ISI GroupMaintainsOutperform—
4 Apr 2024Evercore ISI GroupMaintainsOutperform—
4 Jan 2024Evercore ISI GroupUpgradeOutperform—
4 Jan 2021Evercore ISI GroupDowngradeIn-Line—
10 Nov 2020KeybancInitiatesSector Weight—
10 Nov 2020KeyBancInitiatesSector Weight—
2 Oct 2020JP MorganInitiatesNeutral—
4 Dec 2019JefferiesInitiatesBuy—
26 Aug 2019Evercore ISI GroupInitiatesOutperform—
10 June 2016Sidoti & Co.DowngradeNeutral—
10 Feb 2016Janney CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MLAB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MLAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Mesa Laboratories, Inc. returned +93.0% against +17.5% for the S&P 500, dividends included.

MLAB vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Oct 25Jan 26Apr 26Jul 26MLABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+84.6%
Analysts raising
0
Analysts cutting
1
Fundamentals

Mesa Laboratories, Inc. (MLAB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
140.6×

Cheaper than 5% of US stocks

Price / sales
2.7×

Cheaper than 44% of US stocks

Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
18.1×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
1.0%

Higher than 29% of US stocks

Earnings growth (YoY)
−40.3%

Higher than 13% of US stocks

Gross margin
64.9%

Higher than 78% of US stocks

Operating margin
11.7%

Higher than 67% of US stocks

Net margin
1.9%

Higher than 52% of US stocks

Returns & dividend
Return on equity
2.7%

Higher than 49% of US stocks

Return on assets
3.3%

Higher than 67% of US stocks

Dividend yield
0.5%

Higher than 10% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mesa Laboratories, Inc. (MLAB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mesa Laboratories, Inc. has a market value of $676.6M and an enterprise value of $822.5M.

  • Revenue in the twelve months to 30 June 2026: $249.7M. The latest quarter grew 1.0% year on year.

  • Net income over the same four quarters: $4.8M, a 1.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.84.

  • Free cash flow in the twelve months to 30 June 2026: $52.9M.

  • Mesa Laboratories, Inc. spent $3.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 5.6M.

  • Trailing P/E: 140.6×; forward P/E: 11.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.53%, paying out 75% of earnings.

  • Mesa Laboratories, Inc. employs 717 people — $348K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

MLAB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelScientific & Technical Instruments
CompanyMarket capTKN rank
MLABMesa Laboratories, Inc.$676.6M
91
VPGVishay Precision Group, Inc.$819.6M
61
ITRNIturan Location & Control Ltd.$1.0B
100
USBCUSBC, Inc.$177.9M
6
BMIBadger Meter, Inc.$3.7B
40
ITRIItron, Inc.$4.1B
75
VNTVontier Corp.$4.4B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mesa Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MLAB news & analysis

Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of Mesa Laboratories, Inc.'s (MLAB) first-quarter fiscal 2027 earnings call. The item provides the transcript of management's discussion during the call, though no details from the call itself are included in the excerpt.

Why it matters — A MLAB watcher would care because the earnings-call transcript offers direct insight into management's commentary on the company's quarterly results and outlook.

Mesa Laboratories Q1 Earnings Call Highlights

MarketBeat · 11 Aug 2026neutral

Mesa Laboratories reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins, and continued debt reduction. Newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in the Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.

Why it matters — The report provides MLAB watchers with an update on the new CEO's priorities for fixing fulfillment problems and speeding up product development in key business segments.

Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call

GlobeNewsWire · 3 Aug 2026neutral

Mesa Laboratories announced it will release financial results for its first fiscal quarter ended June 30, 2026 after market close on August 10, 2026. The company will hold its inaugural earnings conference call that same day at 4:30 p.m. Eastern Time, concluding with a Q&A session with analysts.

Why it matters — Mesa Labs watchers would care because this sets the dates for the company's first-quarter earnings release and its first earnings conference call with analysts.

FAQ

Frequently asked questions about MLAB stock

What is the MLAB stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Mesa Laboratories, Inc. have a median 12-month price target of $118, with estimates ranging from $110 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLAB stock a buy right now?

Of the 3 analysts covering Mesa Laboratories, Inc., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mesa Laboratories, Inc. 91 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLAB?

As at 10 Sept 2026, Mesa Laboratories, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will MLAB stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies -2.8% from the last close, and Ticker Nerd's factor model ranks Mesa Laboratories, Inc. 91 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLAB stock forecast for 2030?

No analyst covering Mesa Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $125 over the next 12 months.

How has MLAB stock performed over the past year?

Mesa Laboratories, Inc. returned +93.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mesa Laboratories, Inc. do?

Mesa Laboratories, Inc. is a life sciences tools and critical quality control solutions company that develops, manufactures, sells, and services products used in regulated environments.

What is the latest news on MLAB?

The most recent item we track (Seeking Alpha, 11 Aug 2026): "Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript". Seeking Alpha published the transcript of Mesa Laboratories, Inc.'s (MLAB) first-quarter fiscal 2027 earnings call. The item provides the transcript of management's discussion during the call, though no details from the call itself are included in the excerpt.

Company

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. is a life sciences tools and critical quality control solutions company that develops, manufactures, sells, and services products used in regulated environments. Its portfolio supports monitoring, testing, measurement, and calibration across healthcare, pharmaceutical, food and beverage, and medical device markets. The company’s operations are organized into Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions, reflecting its focus on product safety, process reliability, and compliance. Mesa Laboratories serves customers in North America, Europe, the Asia Pacific, and other international markets, making it an important supplier of specialized instruments, disposable products, and validation tools for quality-sensitive industries. Mesa Laboratories, Inc. is headquartered in Lakewood, Colorado.

CEO Dr. Siddhartha Chandrakant Kadia B.E., M.S., Ph.D. · 717 employees · United States · https://www.mesalabs.com